

June 3, 2025

County of Ventura Board of Supervisors

Subject: Ratification, and Approval to increase Three Physician Service Contracts for Contract Year 2024-25, by \$133,882 from \$826,990 to \$960,872, and Increase Two of These Physician Service Contracts for Contract Year 2025-26 by \$124,000 from \$616,800 to \$740,800; and Approval of Two New Physician Service Contracts for Contract Year 2025-26 Totaling \$948,600; Delegation of Authority to Make Limited Modifications and Extend the Term of the Agreements. (Levine Act Item).

Recommendations:

1. That your Board ratify, approve, and authorize the Purchasing Agent or designee to sign, the third Amendment to County Contract No. 8617 with Children's Hospital Los Angeles Medical Group, Inc. (CHLA), for pediatric ophthalmology services, adding one extra full clinic day per month, and increasing the contract not-to-exceed amount by \$4,000 from \$60,500 to \$64,500 for Contract Year 2024-25, effective May 1, 2025, through June 30, 2025, and by \$24,000 from \$61,500 to \$85,500 per contract year thereafter (Exhibit 4);
2. That your Board approve, and authorize the HCA Director or designee to sign, agreement with Amanda Lo, M.D., (Dr. Lo) for pathology services, in the amount of \$348,600 for Contract Year 2025-26, effective July 1, 2025, through June 30, 2026, and any contract year thereafter. (Exhibit 5);
3. That your Board approve, and authorize the HCA Director or designee to sign, agreement with William E. Starr, M.D., A Professional Corporation (Dr. Starr) for plastic surgery services, in the amount of \$600,000 for Contract Year 2025-26, effective July 1, 2025, through June 30, 2026, and any contract year thereafter. (Exhibit 6);
4. That your Board approve, and authorize the Purchasing Agent or designee to increase the purchase document for Fahradyan Plastic Surgery (Dr. Fahradyan) by \$123,941 from \$555,300 to \$679,241 for the period of August 1, 2024, through July 31, 2025, and by \$100,000 from \$555,300 to \$655,300 for the period August 1, 2025 through July 31, 2026 and any contract year thereafter, effective June 3, 2025;

5. That your Board approve, and authorize the HCA Director or designee to increase, purchase document for pathology services with Michael A. Richardson, M.D. (Dr. Richardson) by \$5,941 from \$211,190 to \$217,131, for the period of July 1, 2024, through June 30, 2025, due to Dr. Richardson submitting a prorated bonus invoice after his resignation on March 1, 2025, effective June 3, 2025.
6. Authorization for the HCA Director or Purchasing Agent to amend the agreements in recommendations 1- 4 to (a) allocate funds between different compensation categories within the not-to-exceed amount specified in the purchase document; (b) make budget modifications that do not increase the total amount of the purchase document; (c) and implement corrections, clarifications, business entity name changes (excluding Taxpayer ID Number changes), and technical adjustments to the agreement and purchase document, provided that these changes align with the original purpose of the agreements and do not incur additional costs to the County. All amendments are subject to review and approval by County Counsel.
7. Authorization for the HCA Director or Purchasing Agent to extend the term of the agreements by amendment, for up to two (2) additional periods of one (1) year each following the completion of the current agreement term, on the same or more favorable terms and conditions (with any changes in the Responsibilities of Contractor to be consistent with the original purpose of the agreements), and for up to a 15% increase per contract year (within the fair market value) of the not to exceed amount of the purchase document. All extensions would be subject to all necessary prior appropriations and other budgetary approvals by your Board and review and approval as to form by County Counsel.

Reason For Ratification

HCA authorized CHLA to provide services under the terms of the amendment effective May 1, 2025, in anticipation of your Board’s approval.

Fiscal Impact:

| | <u>CY 2024-25</u> | <u>CY 2025-26</u> |
|--------------------|-------------------------------------|-------------------|
| Revenues | \$133,882 | \$1,072,600 |
| Costs | \$133,882 | \$1,072,600 |
| Net County Cost | \$0 | \$0 |
| Funding Source: | VCMC Operating Revenues/Collections | |
| Match Requirement: | None | |

Table 1 below summarizes the net financial impacts for Contract Year 2024-25:
Contains the requests for CY 2024-25 for Various Physician Services

| Provider | Contract / Purchase Document | CY 2024-2025 | CY 2024-2025 | CY 2024-2025 |
|------------------------------|------------------------------|------------------|------------------------|-------------------|
| | | ENCUMBRANCE | INCREASE or <DECREASE> | TOTAL ENCUMBRANCE |
| Fahradyan Plastic Surgery | SC 3300202*073100000003 | \$ 555,300 | \$ 123,941 | \$ 679,241 |
| CHLA (Dr. Lee) Ophthalmology | CT 3300FY2*000000000412 | \$ 60,500 | \$ 4,000 | \$ 64,500 |
| Michael A. Richardson, M.D. | PD 33002024062400000048 | \$ 211,190 | \$ 5,941 | \$ 217,131 |
| Total | | \$826,990 | \$133,882 | \$960,872 |

Table 2 below summarizes the net financial impacts for Contract Year 2025-26:
Contains the requests for CY 2025-26 for Various Physician Services

| Provider | Contract / Purchase Document | CY 2025-2026 | CY 2025-2026 | CY 2025-2026 |
|------------------------------|------------------------------|------------------|------------------------|--------------------|
| | | ENCUMBRANCE | INCREASE or <DECREASE> | TOTAL ENCUMBRANCE |
| Fahradyan Plastic Surgery | SC 3300202*073100000003 | \$ 555,300 | \$ 100,000 | \$ 655,300 |
| CHLA (Dr. Lee) Ophthalmology | CT3300FY2*000000000412 | \$ 61,500 | \$ 24,000 | \$ 85,500 |
| Amanda E. Lo, M.D. | Pending PD# - New Agreement | \$ - | \$ 348,600 | \$ 348,600 |
| William E. Starr, M.D. | Pending PD# - New Agreement | \$ - | \$ 600,000 | \$ 600,000 |
| Total | | \$616,800 | \$1,072,600 | \$1,689,400 |

Discussion:

CHLA – Pediatric Ophthalmology Services (Recommendation 1) – CHLA has proven to be an invaluable partner to the HCA, significantly expanding outpatient pediatric services to offer a diverse range of specialty care to the community. To help meet increased patient demand and maintain high standards of care, the amendment before your Board adds one additional full ophthalmology clinic date per month. This results in an increase of \$4,000 for Fiscal Year 2024–25 and \$24,000 for any fiscal year thereafter to the contract’s not-to-exceed amount. Exhibits 1–3 contain the agreement and prior amendments for the Board’s reference.

Dr. Lo (Recommendation 2) – Dr. Amanda Lo is a new provider at our facility, specialized in Hematopathology. She earned her Doctor of Medicine degree from the University of New Mexico School of Medicine in 2011. Dr. Lo completed her residency in Pathology-Anatomic and Clinical at Cedars-Sinai Medical Center from 2012 to 2016. She further advanced her expertise by completing a fellowship in Hematopathology at Duke University Medical Center from 2016 to 2017. Dr. Lo holds board certifications in Hematopathology and Anatomic/Clinical Pathology from the American Board of Pathology and maintains an active California medical license. Her strong academic background and specialized training will significantly enhance the pathology services provided at our facility.

With your Board’s approval, the agreement with Dr. Lo, subject to all necessary budgetary approvals by your Board, shall remain in effect through June 30, 2026. Then, unless a party gives notice of its intent not to renew at least 90 days prior to the renewal date, and subject to the receipt of all necessary budgetary approvals by your Board, the agreement shall then be extended for up to two additional periods of one year each.

Dr. Starr (Recommendation 3) – The agreement before your Board is for William E. Starr, M.D. Dr. Starr received his Medical Degree from Universidad Autonoma de Guadalajara, in Guadalajara, Mexico and completed his residency at Albany Medical Center Hospital. He is board certified in plastic surgery, hand surgery and otolaryngology.

Dr. Starr has been in our system for the past 39 years working on cases of plastic surgeries, hand injuries, burn victims, and other medically necessary reconstructive procedures caused by disease such as cancer, accidents and trauma. Dr. Starr has been the Medical Director of the Plastic and Reconstructive Surgery Department since 1986, and the Medical Director, Wound Care Program Services since 2022. Under the terms of the new agreement, Dr. Starr will continue serving as an attending physician and as the Medical Director of the Plastic and Reconstructive Surgery Department; however, by mutual agreement, he will no longer hold the role of Medical Director for the Wound Care Program.

With your Board's approval, the agreement with Dr. Starr, subject to all necessary budgetary approvals by your Board, shall remain in effect through June 30, 2026. Then, unless a party gives notice of its intent not to renew at least 90 days prior to the renewal date, and subject to the receipt of all necessary budgetary approvals by your Board, the agreement shall then be extended for up to two additional periods of one year each.

Dr. Fahradyan (Recommendation 4) – The purchase document not-to-exceed amount for Dr. Fahradyan will be increased by \$123,941 for Contract Year 2024-25 and \$100,000 for contract year thereafter, to ensure uninterrupted payment for his services. This increase is necessary as Dr. Fahradyan will surpass the projected productivity levels for contract year.

Dr. Richardson (Recommendation 5) – On April 29, 2025, your Board approved a Board Letter to decrease the maximum contract compensation for Dr. Richardson, following his resignation. However, Dr. Richardson later submitted a prorated invoice for his bonus incentive, resulting in an increase of \$5,941 to the total amount paid for the period of July 1, 2024, through June 30, 2025.

The portions of the agreements and amendment concerning compensation paid by the Healthcare Agency are exempt from disclosure under the Public Records Act (Health and Safety Code Section 1457 (c) (1)). If the Board would like further information regarding the rates, the original documents are retained by Mike Taylor, HCA's Chief Financial Officer.

Strategic Plan Priority:

The item presented in this Board letter supports the Healthy, Safe, and Resilient Communities strategic priority of the County Strategic Plan as it is designed to meet the goal of providing access to quality healthcare required for our community to thrive.

This letter has been reviewed by the County Counsel, the Auditor-Controller's Office, the County Executive Office and General Services Agency. If you have any questions regarding this item, please call John Fankhauser, M.D., Chief Executive Officer, County Hospitals, at 805-652-6058 or Vikram Kumar, M.D., Chief Executive Officer, Ambulatory Care, at 805-677-5223.



Theresa Cho, MD, MHA
Health Care Agency Director

Attachments:

- Exhibit 1 – Agreement with Children's Hospital Los Angeles Medical Group, Inc. for Pediatric Ophthalmology Services.
- Exhibit 2 – First Amendment to the Agreement with Children's Hospital Los Angeles Medical Group, Inc. for Pediatric Ophthalmology Services.
- Exhibit 3 – Second Amendment to the Agreement with Children's Hospital Los Angeles Medical Group, Inc. for Pediatric Ophthalmology Services.
- Exhibit 4 – Third Amendment to the Agreement with Children's Hospital Los Angeles Medical Group, Inc. for Pediatric Ophthalmology Services.
- Exhibit 5 – Agreement for Pathology Services with Amanda E. Lo, M.D.
- Exhibit 6 – Agreement for Plastic Surgery Services with William E. Starr, M.D.